L. Lindblad

[PP.02.17] SUCCESSFUL COMPLETION OF A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE TRIAL FOR THE FIRST IN CLASS ANGIOTENSIN AT2-RECEPTOR AGONIST COMPOUND 21

M. Scheinin, P. Korhonen, T. Unger, 2017 .

Developing new marine antifouling substances: learning from the pharmaceutical industry

L. Mårtensson Lindblad, L. Lindblad, 2009 .

Organic alternatives to copper in the control of marine biofouling

Miriam Pérez, G. Blustein, M. Stupak, 2009 .

The Angiotensin AT2-Receptor Agonist Compound 21 Is an Antagonist for the Thromboxane TP-Receptor – Implications for Preclinical Studies and Future Clinical Use

M. Nybo, M. Bloksgaard, J. Mey, 2023, Peptides.

Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach.

Chad H. Jones, M. Waters, C. Sumners, 2018, Clinical science.

The angiotensin AT2-receptor agonist compound 21 is an antagonist for the thromboxane TP-receptor – Implications for preclinical studies and future clinical use

M. Nybo, M. Bloksgaard, J. Mey, 2023, Peptides.